DBV Technologies (DBVT) Total Liabilities (2014 - 2026)
DBV Technologies (DBVT) reported Total Liabilities of $58.4 million for Q1 2026, up 22.46% year-over-year from $47.7 million in Q1 2025, and down 10.02% on a QoQ basis from $64.9 million in Q4 2025.
DBV Technologies (DBVT) has 13 years of Total Liabilities data on file, last reported at $58.4 million in Q1 2026.
- Quarterly Total Liabilities rose 22.46% year-over-year to $58.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.4 million (up 22.46% YoY) and the FY2025 annual result came in at $64.9 million, up 69.58% from the prior year.
- Total Liabilities slipped to $58.4 million in Q1 2026 per DBVT's latest filing, from $64.9 million in the prior quarter.
- Across five years, Total Liabilities topped out at $64.9 million in Q4 2025 and bottomed at $34.2 million in Q1 2024.
- The 5-year median for Total Liabilities is $45.8 million (2023), against an average of $46.6 million.
- The widest annual swing landed in 2024, when Total Liabilities slumped 36.4%; it then jumped 69.58% in 2025.
- Tracing DBVT's Total Liabilities over 5 years: stood at $52.1 million in 2022, then retreated by 17.8% to $42.8 million in 2023, then declined by 10.58% to $38.3 million in 2024, then soared by 69.58% to $64.9 million in 2025, then retreated by 10.02% to $58.4 million in 2026.
- Per Business Quant, the three latest DBVT Total Liabilities figures stand at $58.4 million (Q1 2026), $64.9 million (Q4 2025), and $57.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | 58.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.40 Mn |
| Dec 31, 2025 | 64.90 Mn |
| Sep 30, 2025 | 57.64 Mn |
| Jun 30, 2025 | 57.21 Mn |
| Mar 31, 2025 | 47.69 Mn |
| Dec 31, 2024 | 38.27 Mn |
| Sep 30, 2024 | 39.02 Mn |
| Jun 30, 2024 | 35.10 Mn |
| Mar 31, 2024 | 34.24 Mn |
| Dec 31, 2023 | 42.80 Mn |
| Sep 30, 2023 | 45.79 Mn |
| Jun 30, 2023 | 53.28 Mn |
| Mar 31, 2023 | 53.83 Mn |
| Dec 31, 2022 | 52.06 Mn |
| Sep 30, 2022 | 36.07 Mn |
| Jun 30, 2022 | 40.56 Mn |
| Mar 31, 2022 | 35.52 Mn |
| Dec 31, 2021 | 47.45 Mn |
| Sep 30, 2021 | 54.03 Mn |
| Jun 30, 2021 | 57.57 Mn |
| Mar 31, 2021 | 52.23 Mn |
| Dec 31, 2020 | 66.75 Mn |
| Sep 30, 2020 | -233.10 Mn |
| Jun 30, 2020 | 324.01 Mn |
| Mar 31, 2020 | -299.66 Mn |
| Dec 31, 2019 | 262.08 Mn |
| Sep 30, 2019 | 167.66 Mn |
| Jun 30, 2019 | 205.68 Mn |
| Dec 31, 2018 | 192.59 Mn |
| Jun 30, 2018 | 295.10 Mn |
| Dec 31, 2017 | 206.41 Mn |
| Jun 30, 2017 | 258.88 Mn |
| Dec 31, 2016 | 307.76 Mn |
| Jun 30, 2016 | 370.67 Mn |
| Dec 31, 2015 | 376.28 Mn |
| Jun 30, 2015 | 129.34 Mn |
| Dec 31, 2014 | 12.46 Mn |